The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Ihab I Elhajj - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind placebo controlled trial of rifaximin in patients with abdominal bloating and Flatulence
The American Journal of Gastroenterology, 2006Co-Authors: Ala I Sharara, Elie Aoun, Heitham Abdulbaki, Rawad Mounzer, Shafik Sidani, Ihab I ElhajjAbstract:A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence
Diane R Krieger - One of the best experts on this subject based on the ideXlab platform.
-
a prospective randomized double blind placebo controlled parallel group dual site trial to evaluate the effects of a bacillus coagulans based product on functional intestinal gas symptoms
BMC Gastroenterology, 2009Co-Authors: Douglas S Kalman, Howard I Schwartz, Patricia Jaramillo Alvarez, Samantha Feldman, John Pezzullo, Diane R KriegerAbstract:Background This randomized double blind placebo controlled dual site clinical trial compared a probiotic dietary supplement to placebo regarding effects on gastrointestinal symptoms in adults with post-prandial intestinal gas-related symptoms (abdominal pain, distention, Flatulence) but no gastrointestinal (GI) diagnoses to explain the symptoms.
Ala I Sharara - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind placebo controlled trial of rifaximin in patients with abdominal bloating and Flatulence
The American Journal of Gastroenterology, 2006Co-Authors: Ala I Sharara, Elie Aoun, Heitham Abdulbaki, Rawad Mounzer, Shafik Sidani, Ihab I ElhajjAbstract:A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence
Thomas Betsche - One of the best experts on this subject based on the ideXlab platform.
-
comparative effect of boiling and solid substrate fermentation using the tempeh fungus rhizopus oligosporus on the Flatulence potential of african yambean sphenostylis stenocarpa l seeds
Food Chemistry, 2007Co-Authors: Marshall A Azeke, Barbara Fretzdorff, Hans Bueningpfaue, Thomas BetscheAbstract:The tropical African yambean (AYB, Sphenostylis stenocarpa L.) is a protein-rich underutilized African legume. The presence of the Flatulence- and diarrhoea-causing raffinose family oligosaccharides (RFO: raffinose, stachyose and verbascose) or α-galactosides has limited the food use of African yambean seeds. To reduce this limitation, non-traditional processing methods are required. Seeds of three varieties were (i) examined for the Flatulence- and diarrhoea-causing RFO and (ii) fermented with Rhizopus oligosporus for tempeh production. The traditional tempeh production process involved dehulling, soaking in water for 24 h, boiling in water for 30 min, inoculation and fermentation. In addition, the traditional tempeh procedure was modified by using 1% citric acid solution instead of water for soaking and cooking. Comparisons with traditionally cooked beans, which involved boiling in water for 4 h, were made. Boiling seeds for 4 h resulted in 8-30% reduction of total α-galactosides in the three varieties, while the traditional tempeh procedure resulted in an almost complete loss (98%) of the same (P < 0.05). The modified procedure resulted in a bacteria-free tempeh but α-galactoside reduction was 22-39%. Both tempeh production processes were clearly more effective than was traditional cooking in reducing the Flatulence potential of the AYB seeds.
Alan R Zinsmeister - One of the best experts on this subject based on the ideXlab platform.
-
a randomized controlled trial of a probiotic combination vsl 3 and placebo in irritable bowel syndrome with bloating
Neurogastroenterology and Motility, 2005Co-Authors: M Vazquez I Roque, Michael Camilleri, Debra Stephens, Duane Burton, Kari Baxter, G M Thomforde, Alan R ZinsmeisterAbstract:Abstract Aim: To evaluate the effects of a combination probiotic on symptoms and colonic transit in patients with irritable bowel syndrome (IBS) and significant bloating. Methods: Forty-eight patients with Rome II IBS were randomized in a parallel group, double-blind design to placebo or VSL# 3 twice daily (31 patients received 4 weeks and 17 patients 8 weeks of treatment). Pre- and post-treatment colonic transit measurements were performed using scintigraphy with 111In charcoal. Symptoms were summarized as an average daily score for the entire period of treatment and separately for the first 4 weeks of treatment. Weekly satisfactory relief of abdominal bloating was assessed. Results: Treatment with VSL# 3 was associated with reduced Flatulence over the entire treatment period (placebo 39.5 ± 2.6 vs VSL# 3 29.7 ± 2.6, P = 0.011); similarly, during the first 4 weeks of treatment, Flatulence scores were reduced (placebo 40.1 ± 2.5 vs VSL# 3 30.8 ± 2.5, P = 0.014). Proportions of responders for satisfactory relief of bloating, stool-related symptoms, abdominal pain and bloating scores were not different. Colonic transit was retarded with VSL# 3 relative to placebo (colon geometric center 2.27 ± 0.20 vs 2.83 ± 0.19, P = 0.05 respectively). Conclusion: VSL# 3 reduces Flatulence scores and retards colonic transit without altering bowel function in patients with IBS and bloating.